In July 2002, a large hormone therapy trial was stopped early and the news went everywhere: hormone replacement therapy causes breast cancer and heart attacks. Within a year, prescriptions fell off a cliff. Millions of women stopped their therapy, and a generation of younger women never started. The trial was the Women's Health Initiative, the WHI, and the fear it produced was real and lasting. The problem is that the headline was a poor summary of the actual data, and the reanalysis of that same data over the following two decades tells a different and more useful story. Here is what the trial found, where the myths came from, and what changed.

What the WHI Was

The WHI was a set of large randomized trials, the strongest study design there is, run in the US and published starting in 2002 and 2004 (JAMA 2002; 2004). It tested two regimens against placebo: conjugated equine estrogen plus a synthetic progestin (medroxyprogesterone acetate) in women with a uterus, and estrogen alone in women who had had a hysterectomy. It enrolled tens of thousands of women, which is why its results carried so much weight.

The catch is in who it enrolled. The average participant was about 63 years old at the start, more than a decade past the typical age of menopause. The trial was designed to study disease prevention in older women, not symptom relief in women just entering the transition. That design choice is the root of nearly every myth that followed.

Myth 1: HRT Causes Breast Cancer

The combined arm, estrogen plus the synthetic progestin, did show a small increase in breast cancer diagnoses over time. That part is real and should not be waved away. But the size and the source matter. The increase was small in absolute terms, it appeared after several years of use, and it showed up in the combined arm, the one with the synthetic progestin.

The estrogen-alone arm told the opposite story. Women who took estrogen by itself (because they had no uterus) did not show an increase in breast cancer, and over long follow-up some analyses found a lower breast cancer rate than placebo. That single contrast undercuts the blanket claim. If estrogen itself were the breast cancer driver, the estrogen-alone arm should have looked worse, and it did not. The signal tracked with the combined regimen, which has shifted attention to the progestin component and the type of progestogen used.

Myth 2: HRT Causes Heart Attacks

This is where the age problem becomes decisive. The early headline reported increased cardiovascular events, but when researchers stratified the results by age and by years since menopause, the picture split in two.

Among women who started therapy in their 50s or within ten years of menopause, hormone therapy was not associated with the heart harm seen in the overall average. In the estrogen-alone trial, women aged 50 to 59 at baseline actually showed a lower risk of heart attack and lower coronary artery calcification than placebo (Manson et al.; WHI follow-up analyses, JAMA 2013 and later). Among women who started in their 70s, well past menopause, the risk went the other way. Pooling those two groups into one average produced a number that described neither group well, and that average is what scared everyone in 2002.

The Timing Hypothesis

This age split is the basis of what is now called the timing hypothesis. The idea is that estrogen's effect on arteries depends on the state of those arteries when you start. Begin near menopause, when blood vessels are relatively healthy, and estrogen appears neutral to beneficial for the heart. Begin many years later, when atherosclerosis has set in, and estrogen may destabilize existing disease. Same drug, opposite effect, depending on when you start.

Two trials designed specifically to test timing support this. ELITE (the Early versus Late Intervention Trial with Estradiol) and KEEPS (the Kronos Early Estrogen Prevention Study) both studied women closer to menopause and found a more favorable vascular profile than the older WHI population showed. The timing hypothesis is now reflected in major guidelines.

Myth 3: HRT Causes Dementia

The "probable dementia" warning that sat in the boxed label for years came from a WHI substudy, WHIMS, that enrolled only women aged 65 and older. It found increased dementia risk in that age group on combined therapy. The trap is the same as with the heart data: that result describes women starting hormones in their late 60s and 70s, not women starting in their early 50s for hot flashes. Generalizing the dementia finding to younger starters was never supported by the data, and the FDA removed the probable-dementia language from the boxed warning in November 2025.

Why the Picture Changed Officially

For two decades the boxed warning carried the 2002 framing. Then in November 2025, after an expert panel and public comment, the FDA removed the boxed warning language on cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products and called for age-specific labeling. The Menopause Society's 2022 position statement and its 2025 commentary had already endorsed individualized therapy and supported starting hormone therapy in symptomatic women under 60 or within ten years of menopause. The science did not flip. The reanalysis caught up with the boxed warning, and the warning was finally updated to match.

What This Does Not Mean

The reread cuts both ways, and honesty requires the limits. Hormone therapy is not risk-free. For women well past menopause or with significant cardiovascular disease, the older WHI cautions still apply, and the Menopause Society reaffirmed that real risk remains for that group. A personal history of breast cancer, blood clots, stroke or active liver disease still weighs against systemic estrogen regardless of any label change. The combined-therapy breast cancer signal is small but real. The lesson of the WHI reanalysis is not that hormones are safe for everyone. It is that the 2002 headline lumped a 75-year-old and a 52-year-old into one number, and that number fit neither.

The Takeaway

The WHI was good science reported badly. Its average results, drawn from a population over a decade past menopause, were generalized to women they did not describe. The age-stratified reanalysis and the timing hypothesis show a favorable benefit-risk balance for symptomatic women who start near menopause, which is exactly the group most likely to want treatment. If hot flashes, night sweats, or broken sleep are wearing you down and you are under 60 or within ten years of your last period, the WHI is not the reason to stay away. It is the reason the conversation can finally be honest.

Reviewed By

[Reviewed by: clinician name, credential. Last reviewed: date.]

Wondering whether the updated evidence changes your options? Start an intake and a licensed clinician will review your age, history and risk profile to see whether hormone therapy fits.

This article is for education and is not a substitute for individual medical advice from your own clinician.